新辅助化疗在胃癌患者中的应用体会

Experience of Neoadjuvant Chemotherapy in Patients with Gastric Cancer

目的研究并分析治疗胃癌患者时使用新辅助化疗的效果。方法整群收集2013年4月—2015年1月该院收治的胃癌患者共65例,根据平行、单盲、随机对照的设计原则分为对照组（32例）和观察组（33例）,对照组使用奥沙利铂和卡培他滨进行辅助化疗,观察组使用奥沙利铂和替吉奥进行辅助化疗,将两组患者6个月、12个月的生存率以及手术切除率进行观察和对比。结果观察组与对照组患者6个月的生存率分别为87.9%、84.4%,χ^2=0.167,P=0.683;观察组与对照组患者12个月的生存率分别为66.7%、59.4%,χ^2=0.371,P=0.543;观察组与对照组患者手术切除率分别为75.8%、71.9%,χ^2=0.127,P=0.722,差异有统计学意义。结论在胃癌患者的治疗过程中,奥沙利铂联合卡培他滨或者替吉奥均能够使患者获得良好的远期受益,患者的生存率均得到改善,提示新辅助化疗方式值得推广应用。

Objective To study and analyze the use of neoadjuvant chemotherapy in the treatment of patients with gastric cancer effect. Methods Group selection a total of 65 cases of patients with gastric cancer from April 2013 to Ianuary 2015,according to a parallel, single-blind, randomized, controlled design principles into the control group（32 cases） and observation group（33 cases） and control group using oxaliplatin and capecitabine adjuvant chemotherapy, observation group and Gio oxaliplatin adjuvant chemotherapy, two groups of patients for 6 months, 12 months, survival and resection rate were observed and compared. Results The observation group and control group of patients six months survival rates were 87.9%,84.4%, χ^2= 0.167, P= 0.683; observation group and control group were 12 months survival rates were 66.7%, 59.4%, χ^2=0.371, P = 0.543; observation group and the control group of patients resection rate was respectively 75.8%, 71.9%, χ^2=0.127, P = 0.722. Conclusion In the treatment of gastric cancer patients, oxaliplatin plus capecitabine or Gio patients are able to get a good long-term benefit of the patient survival rate is improved, suggesting that neoadjuvant chemotherapy approach should be widely applied.